Pasithea Therapeutics Corp

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner. No deal terms were disclosed.

Pasithea, Evotec Ink Drug Development Pact

-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the initiation of a new chemical entity (“NCE”) development program and named Evotec as its NCE research partner.

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement.

Evotec SE

-- Company contracts leading global drug development company to advance initial drug candidate -- -- Company contracts leading global drug development company to advance initial drug candidate --

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

News for Pasithea Therapeutics Corp Stock (KTTA)